Evidence map›Paper›PMID 38381937›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2024

Addressing controversial areas in the management of advanced prostate cancer in Canada Areas of consensus and controversy from the third Canadian consensus forum.

Fred Saad, Sebastien J Hotte, Krista Noonan, Shawn Malone, Christopher Morash, Tamim Niazi, Ricardo A Rendon, Bobby Shayegan, Naveen S Basappa, Ilias Cagiannos and 16 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 17 institutions in 2 countries.

Fred SaadCentre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada.
Sebastien J HotteJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Krista NoonanBC Cancer Agency, University of British Columbia, Surrey, BC, Canada.
Shawn MaloneThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Christopher MorashJewish General Hospital, McGill University, Montreal, QC, Canada.
Tamim NiaziJewish General Hospital, McGill University, Montreal, QC, Canada.
Ricardo A RendonQueen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
Bobby ShayeganSt. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
Naveen S BasappaCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Ilias CagiannosThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Brita DanielsonCross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Guila DelouyaCentre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada.
Ricardo FernandesLondon Health Science Centre, Western University, London, ON, Canada.
Cristiano FerrarioJewish General Hospital, McGill University, Montreal, QC, Canada.
Antonio FinelliPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Geoffrey T GottoSouthern Alberta Institute of Urology, University of Calgary, Calgary, AB, Canada.
Robert J HamiltonPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Jason P IzardKingston Health Sciences Centre, Queen's University, Kingston, ON.
Anil KapoorSt. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
Aly-Khan LalaniJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
Luke T LavalléeThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Michael OngThe Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Frédéric PouliotQuebec City University Hospital Center & Centre de Recherche of Quebec City University Hospital Center, University of Laval, QC, Canada.
Alan I SoProstate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.
Steven YipTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Kim N ChiBC Cancer Agency, University of British Columbia, Vancouver, BC, Canada.
University of Ottawa · CABC Cancer Agency · CACentre Hospitalier de l’Université de Montréal · CAMcGill University · CAMcMaster University · CAUniversity of Alberta · CAUniversity of Calgary · CADalhousie University · CAJewish General Hospital · CAJuravinski Cancer Centre · CAPrincess Margaret Cancer Centre · CAQueen's University · CASt. Joseph’s Healthcare Hamilton · CAUniversité Laval · CAUniversity of Toronto · CAVancouver General Hospital · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe management of prostate cancer (PCa) is rapidly evolving. Treatment and diagnostic options grow annually, however, high-level evidence for the use of new therapeutics and diagnostics is lacking. In November 2022, the Genitourinary Research Consortium held its 3

methodsA steering committee of eight multidisciplinary physicians identified topics for discussion and adapted questions from the Advanced Prostate Cancer Consensus Conference 2022 for CCF3. Questions focused on management of metastatic castration-sensitive prostate cancer (mCSPC); use of novel imaging, germline testing, and genomic profiling; and areas of non-consensus from CCF2. Fifty-eight questions were voted on during a live forum, with threshold for "consensus agreement" set at 75%.

resultsThe voting panel consisted of 26 physicians: 13 urologists/uro-oncologists, nine medical oncologists, and four radiation oncologists. Consensus was reached for 32 of 58 questions (one ad-hoc). Consensus was seen in the use of local treatment, to not use metastasis-directed therapy for low-volume mCSPC, and to use triplet therapy for synchronous high-volume mCSPC (low prostate-specific antigen). Consensus was also reached on sufficiency of conventional imaging to manage disease, use of germline testing and genomic profiling for metastatic disease, and poly (ADP-ribose) polymerase (PARP) inhibitors for BRCA-positive prostate cancer.

conclusionsCCF3 identified consensus agreement and provides guidance on >30 practice scenarios related to management of PCa and nine areas of controversy, which represent opportunities for research and education to improve patient care. Consensus initiatives provide valuable guidance on areas of controversy as clinicians await high-level evidence.

Identifiers

PMID38381937
PMCPMC11034961
OpenAlexW4390106584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.